Literature DB >> 30342872

Risk score system for the prediction of hepatocellular carcinoma in patients with type 2 diabetes: Taiwan Diabetes Study.

Tsai-Chung Li1, Chia-Ing Li2, Chiu-Shong Liu3, Wen-Yuan Lin4, Chih-Hsueh Lin4, Sing-Yu Yang5, Cheng-Chieh Lin6.   

Abstract

This study aims to develop a risk score system for hepatocellular carcinoma (HCC) in patients with type 2 diabetes using the Taiwan National Diabetes Care Management Program database. This retrospective cohort study included 31,723 Chinese patients who had type 2 diabetes, aged 30-84 years. Participants were randomly grouped into derivation and validation sets in 2:1 ratio. Cox proportional hazard regression models were used to identify the risk factors of HCC in the derivation set. Discrimination ability of the model was assessed by means of a receiver operating characteristic curve and performance was expressed as the c statistic, assessed internally on validation data sets. The average follow-up was 8.33 years with 748 HCC incident cases in the derivation set. The final HCC risk score system included age (-2 to 8 points), gender (0-2 points), smoking (0-2 points), variation in hemoglobin A1c (0-1 point), serum glutamic-pyruvic transaminase (0-6 points), liver cirrhosis (9 points), hepatitis B (4 points), hepatitis C (3 points), antidiabetes medications (0-3 points), and antihyperlipidemia medications and total/high-density lipoprotein cholesterol ratio (-4 to 2 points). The HCC risk score was the sum of these individual scores (range -6 to 40). The area under the receiver operating characteristic curve for 3-, 5-, and 10-year HCC risks was 0.81, 0.80, and 0.77 for the derivation set, respectively. This HCC risk score system has good prediction accuracy and discriminatory ability, and serves a simple tool for HCC risk prediction.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma; Prediction model; Type 2 diabetes

Mesh:

Substances:

Year:  2018        PMID: 30342872     DOI: 10.1053/j.seminoncol.2018.07.006

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  4 in total

1.  Poorly Differentiated Hepatocellular Carcinoma in a Low-risk Patient with an Otherwise Normal Liver.

Authors:  Nobuhiko Ogasawara; Satoshi Saitoh; Hideyuki Denpou; Keiichi Kinowaki; Norio Akuta; Fumitaka Suzuki; Masashi Hashimoto; Shunichiro Fujiyama; Yusuke Kawamura; Hitomi Sezaki; Tetsuya Hosaka; Masahiro Kobayashi; Yoshiyuki Suzuki; Yasuji Arase; Kenji Ikeda; Takeshi Fujii; Hiromitsu Kumada
Journal:  Intern Med       Date:  2019-10-17       Impact factor: 1.271

Review 2.  How to improve HCC surveillance outcomes.

Authors:  Morris Sherman
Journal:  JHEP Rep       Date:  2019-11-05

3.  Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country.

Authors:  Noor Atika Azit; Shahnorbanun Sahran; Leow Voon Meng; Manisekar Subramaniam; Suryati Mokhtar; Azmawati Mohammed Nawi
Journal:  PLoS One       Date:  2021-12-09       Impact factor: 3.240

Review 4.  Role of Liver-Mediated Tolerance in Nanoparticle-Based Tumor Therapy.

Authors:  Maximiliano L Cacicedo; Carolina Medina-Montano; Leonard Kaps; Cinja Kappel; Stephan Gehring; Matthias Bros
Journal:  Cells       Date:  2020-08-28       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.